A spotlight on movement disorders and schizophrenia at the upcoming Psych Congress Elevate 2022
Psych Congress Elevate will return to Las Vegas, 3–5 June, after two years of virtual meetings. The congress will focus on practical psychopharmacology and future-focused education for mental health clinicians, including those in their early careers. Over three days, attendees will have the opportunity to network with their peers and translate the latest research into clinical application. In this article, we highlight the key schizophrenia and tardive dyskinesia activities taking place at the congress.
Join the conversation!
#Elevate2022
Click here for more information on Psych Congress Elevate
Teva Medical Affairs booth #202
Throughout the congress, attendees will have the opportunity to speak to members of the Teva team at the Medical Affairs booth. Visitors will be able to take home printed infographics on the background, burden and management of tardive dyskinesia, and the treatment of schizophrenia beyond clinical remission. CnsBytes will be available to explore on interactive kiosks.
Click here to find out more about the treatment of schizophrenia beyond clinical remission
Teva-sponsored posters
Don’t miss these posters, which will be displayed from 11:00 AM PT on Friday 3 June. On Saturday 4 June, the posters will be presented at 10:00 AM PT – 11:00 AM PT and 5:10 PM PT – 6:10 PM PT.
- Network Meta-Analysis of Cohort Studies Involving Oral and Long-Acting Injectable Antipsychotic Agents: Administration Frequency and Incidence Rate or Odds of Hospitalization in Schizophrenia
- Early Versus Late Administration of Long-Acting Injectable Antipsychotic Agents Among Patients with Newly-Diagnosed Schizophrenia: An Analysis of a Commercial Claims Database
- IMPACT-TD Registry: Real-World Assessment of the Impact and Progression of Tardive Dyskinesia
Sessions of interest to look out for
Friday 3 June
- Clinical Considerations Regarding the Differential Diagnosis and Management of TD | 12:20 PM PT – 1:30 PM PT
Innovation Theater Lunch presented by Craig Chepke - Breaking Down the Barriers to Utilizing Long-Acting Injectable Antipsychotics for Schizophrenia Management | 2:50 PM PT – 3:50 PM PT
Psychopharmacology session presented by Gregory Mattingly, Britney Pridgen, and Lauren Kennedy West - Coordination of Care Between Referring Psychiatrist and Treatment Center Provider | 6:20 PM PT – 7:30 PM PT
Innovation Theater Dinner presented by Craig Chepke and Lara Shirikjian
Saturday 4 June
- Long- Acting Injectable (LAI) With a Longer Dosing Interval for Adult Patients with Schizophrenia | 7:30 AM PT – 8:40 AM PT
Innovation Theater Breakfast presented by Kevin Ware - TAAR1 Agonism: A Novel Approach to Schizophrenia Management | 1:40 PM PT – 2:40 PM PT
Psychopharmacology session presented by Leslie L. Citrome, Rebecca Kraus, and Bethany Yeiser - Empowered Decision Making: A Treatment Team Approach to Long-Acting Injectables for Adult Clients with Schizophrenia | 6:20 PM PT – 7:30 PM PT
Innovation Theater Dinner presented by Gustavo Alva and Leah Baldwin
Sunday 5 June
- Addressing Persistent Myths and Misconceptions in Tardive Dyskinesia | 10:00 AM PT – 11:00 AM PT
Psychopharmacology session presented by Leslie L. Citrome, Desiree Matthews, and Bethany Yeiser - Tardive Dyskinesia: Overcoming the Challenges of Differential Diagnosis & Treatment in the Era of Telepsychiatry | 12:20 PM PT – 1:30 PM PT
Innovation theater presented by Laxman Bahroo and Jo A. Hughes
